Propanc Biopharma files draft information statement for reverse stock split

• Propanc Biopharma shareholders authorized a reverse stock split of common stock within a 1-for-2 to 1-for-10 range.
• Share count would drop from about 10,331,116 to about 5,165,558 at 1-for-2, or about 1,033,112 at 1-for-10.
• Outstanding options or warrants, if any, would be adjusted to keep total exercise cost roughly unchanged; fractional shares would be rounded up.
• Company targets effectiveness once Nasdaq processes and approves the reverse split.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-046366), on October 08, 2026, and is solely responsible for the information contained therein.